You are here

Oncology Pipeline

Novel therapies, new mechanisms

Pfizer Oncology is committed to discovering, investigating, and developing transformative therapies that improve the outlook for cancer patients worldwide.

Our strong pipeline—one of the most robust in the industry—includes biologics, small molecules, immunotherapies, and biosimilars, and is centered on exploring a wide array of approaches across many tumor types. We seek to translate the most innovative science into meaningful breakthrough medicines that redefine life with cancer for patients.

 

Oncology Pipeline & Trials

Oncology Pipeline Snapshot as of May 1, 2018

  • Discovery Projects
  • Phase 1
    16
  • Phase 2
    4
  • Phase 3
    17
  • Registration
    4
  • Total41
 
Compound Name
Indicationsort descending
Phase
Submission Type
Compound Type
PF-06863135
Therapeutic Area:
Oncology
Phase:Phase 1
Compound Type:Biologic
Business Segment:
WRD
Mechanism of Action:
Bispecific protein
Go to clinical trial
Multiple Myeloma (Biologic) Phase 1 New Molecular Entity Biologic
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic Castrate Resistant Prostate Cancer (PRIORITY REVIEW)
Project advanced
Registration Product Enhancement Small Molecule
Xtandi (enzalutamide)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Androgen receptor inhibitor
Go to clinical trial
Non-metastatic High Risk Hormone Sensitive Prostate Cancer Phase 3 Product Enhancement Small Molecule
Bavencio (avelumab)
Therapeutic Area:
Oncology
Phase:Phase 3
Compound Type:Biologic
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Anti PD-L1 Inhibitor
Go to clinical trial
Platinum Resistant/Refractory Ovarian Cancer (Biologic) Phase 3 Product Enhancement Biologic
Sutent (sunitinib)
Therapeutic Area:
Oncology
Phase:Registration
Compound Type:Small Molecule
Business Segment:
Pfizer Innovative Health
Mechanism of Action:
Multiple Tyrosine Kinase Inhibitor
Go to clinical trial
Renal Cell Carcinoma Adjuvant (E.U.) Registration Product Enhancement Small Molecule
  •  
Select one or more conditions listed below. You can also enter your location (city, state, and/or Zip code) to find a trial near you.Clear Options